BRCA2 and malignant mesothelioma: Similar to these BRCA1 and BRCA2 associated malignancies, malignant mesothelioma patients with germline BRCA mutations are reported to have improved survival and better response to cisplatin-based regimens as well as benefit from PARPi therapy [30, 31].